Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Data on pregnancy outcomes in women with psoriasis are conflicting.
We examined whether maternal psoriasis affects the risk of adverse maternal and pregnancy outcomes.
We used population-based data to compare reproductive patterns in women with and without psoriasis. Odds ratios (ORs) with 95% confidence intervals (CIs) for adverse outcomes were estimated with adjustments for maternal age, period of childbirth, smoking, and prepregnancy body mass index.
Compared with women without psoriasis, women with psoriasis were younger at first birth and had longer interpregnancy intervals but did not differ in final parity. Risk estimates in women with psoriasis were elevated for pregnancy hypertension (OR, 1.37; 95% CI, 1.19-1.58), premature rupture of membranes (OR, 1.15; 95% CI, 1.04-1.27), large for gestational age (OR, 1.11; 95% CI, 1.01-1.21), cleft palate (OR, 1.69; 95% CI, 1.07-2.66), and unspecified malformations (OR, 1.08; 95% CI, 1.01-1.16).
No information was available on lifestyle, disease severity, or type and duration of treatment. Small numbers hampered the assessment of rare outcomes.
Although there was no evidence that fertility is negatively affected, women with psoriasis were at an increased risk of several adverse maternal and pregnancy outcomes. Our findings add to a growing body of evidence that pregnancies in women with psoriasis need special monitoring.Le texte complet de cet article est disponible en PDF.
Key words : malformations, maternal outcomes, pregnancy outcomes, parity, psoriasis, register, Sweden
Abbreviations used : BMI, CI, ICD, ICD10 SE, MGR, MBR, OR
| Drs Weibull and Johansson contributed equally to this article.
| Funding sources: Supported by an Investigator Initiated Research Grant from Pfizer Inc. (IIR WS2059711) and the Karolinska Institutet Research Funds. The sponsors had no role in the study design, data collection, data analysis, data interpretation or writing of the report.
| Disclosure: Dr Lambe owns stocks in AstraZeneca and Pfizer Inc. Drs Bergstrom, Johansson, and Weibull have no conflicts of interest to declare.
| Reprints not available from the authors.